Advertisement
News
Advertisement

Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine

Thu, 08/05/2010 - 8:33am
Bio-Medicine.Org

IRVINE, California, and AMSTERDAM, August 5, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100805/402822-a ) (Photo: http://www.newscom.com/cgi-bin/prnh/20100805/402822-b )

In addition, MammaPrint plays a central role in the recently initiated I-SPY 2 trial, which is a revolutionary breast cancer trial and an initiative of the Biomarkers Consortium, a unique public-private partnership that includes the Food and Drug Administration, the National Institutes of Health, and major pharmaceutical companies, led by the Foundation for the National Institutes of Health. The I-SPY 2 trial, which will enroll patients at 20 leading U.S. cancer research centers, will also rely on Agendia's TargetPrint to provide objective, quantitative information about the expression of the specific tumor-related proteins, E

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading